Therapy for systemic juvenile rheumatoid arthritis with γ‐interferon: A pilot study of nine patients

Abstract
Nine severely ill patients with a confirmed diagnosis of systemic juvenile rheumatoid arthritis were treated with recombinant γ‐interferon (γ‐IFN) in addition to the therapy they were previously receiving for their disease. Improvements in clinical symptoms were noted in 7 of the patients, and median laboratory values also showed a marked improvement after γ‐IFN treatment. A relapse occurred in 1 patient. The results of this study should stimulate further research on the use of γ‐IFN in systemic juvenile rheumatoid arthritis, particularly in determining the appropriate effective dosage.